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Background: Filgrastim or methionyl-granulocyte colony-stimulating factor (Met-G-CSF), is a recombinant
therapeutic protein widely used to treat severe neutropenia caused by myelosuppressive drugs in patients with
nonmyeloid malignancies. In addition to its role in the regulation of granulopoiesis, treatment with G-CSF is
considered the standard approach to mobilize CD34 positive (CD34+) mononuclear cells for reconstituting
hemopoietic ability for bone marrow transplantation. An intended biosimilar filgrastim (coded BK0023) was
produced in GMP conditions by E.coli fermentation according to an original recombinant process and showed
physico-chemical properties and purity profile similar to Neupogen®, a commercial preparation of filgrastim. The
aim of the present study was to demonstrate the comparability of BK0023 to Neupogen® in terms of both in vitro
biological activities and in vivo toxicology, pharmacokinetics and pharmacodynamics.
Methods: Cell proliferation and radioligand binding assays were conducted in NFS-60 cells to compare the biological
activity and functional interaction with the G-CSF receptor in vitro, while preclinical in vivo studies, including
pharmacokinetics and pharmacodynamics after repeated dose were performed in normal and neutropenic rats. A phase I
study was carried out in healthy male volunteers treated by multiple-dose subcutaneous administration of BK0023 and
Neupogen® to evaluate their pharmacodynamic effects as well as their pharmacokinetic and safety profile and to
demonstrate their pharmacodynamic equivalence and pharmacokinetic bioequivalence.
Results: The results reported in this work demonstrate that BK0023 is comparable in terms of biological activity, efficacy
and safety to Neupogen®.
Conclusions: BK0023 has the same pharmacokinetic profile, efficacy and safety as the reference commercial filgrastim
Neupogen® and therefore could be further developed to become a convenient option to treat neutropenia in
oncological patients.
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Human granulocyte-colony stimulating factor (G-CSF) is a
haematopoietic glycoprotein produced by stromal cells,
macrophages, endothelial cells, fibroblasts and monocytes
which binds with high affinity to the G-CSF receptor
expressed on neutrophilic precursor cells in the bone-
marrow, inducing them to proliferate and differentiate into
infection-fighting neutrophils without significant haemo-
poietic effects on other lineages of blood cells.
The use of recombinant G-CSF preparations is a well
established treatment for accelerating bone marrow re-
covery, for preventing the onset of severe myelosuppres-
sion and its correlated complications and for reducing
febrile neutropenia in patients with non-myeloid malig-
nancies under radio- or chemotherapies [1,2]. Moreover,
G-CSF is clinically used as bone marrow mobilizer to in-
crease the number of circulating CD34+ progenitor cells
[3] employed for hematopoietic cell reconstitution. Be-
sides, since recent preclinical evidences showed a pro-
angiogenic potential of CD34+ cells, the use of these
cells for regenerative medicine of ischemic diseases is
currently under investigation in clinical trials [4]. Other
studies suggest that G-CSF is worth investigating as an
interesting therapeutical option in cardiovascular field
for the prevention of restenosis after percutaneous cor-
onary intervention [5] as well as for its beneficial effect
in stroke recovery due to the enhancement of neurogen-
esis and the stimulation of blood vessel formation [6].
In response to the need of a highly purified protein for
medical applications, both glycosylated and non-
glycosylated forms of human G-CSF have been manufac-
tured by recombinant DNA technology. Glycosylation
appears to increase resistance of G-CSF to proteolysis,
but it is not required for receptor binding or biological
activity of the protein. In fact, recombinant glycosylated
and non-glycosylated G-CSF variants exhibit the same
pharmacokinetics and pharmacodynamic profiles [7].
Recombinant Met-G-CSF or filgrastim is a single-
chain protein of 175 aminoacids and two disulfide bonds
differing from the native G-CSF in that it is not O-
glycosylated on threonine 134 and bears an additional
N-terminal methionine required for expression in E. coli.
An original method to produce a biosimilar filgrastim,
called BK0023, by high yield bacterial expression of a fu-
sion protein in the form of inclusion bodies was devel-
oped. After in vitro refolding, the fusion protein was
enzymatically cleaved to give functionally active r-Met-
G-CSF which was purified and characterized. Finally, we
conducted in vitro and in vivo preclinical studies as well
as a clinical phase I study in healthy volunteers to com-
pare the biological, pharmacodynamic, pharmacokinetic
and safety profile of BK0023 and Neupogen®.
The results demonstrated the pharmacodynamic
equivalence and the pharmacokinetic bioequivalence ofBK0023, a recombinant filgrastim produced according to
an original process, towards Neupogen®, a proprietary
filgrastim approved for clinical use, and support the
claim for further assessments of BK0023 as biosimilar
drug that, once approved for marketing, could poten-
tially be a useful and cost-effective treatment option for
patients requiring G-CSF.Methods
Cell culture
Murine myeloblastic NFS-60 cells were purchased from
Cell Line Service (Eppelheim, Germany). RPMI 1640
medium, fetal bovine serum (FBS), fetal calf serum (FCS),
penicillin and streptomycin were provided by Gibco Life
Technologies (Monza, Italy). Mouse interleukine 3 (IL-3)
was from Sigma-Aldrich (St. Louis, MO, USA) while WST-
1 reagent was from Roche (Milan, Italy). Materials for gel
electrophoresis were provided by Bio-Rad Laboratories Inc.
(Hercules, CA, USA). If not otherwise reported, all other
reagents and chemicals were of analytical grade and pro-
vided by Sigma Aldrich-Fluka, Merck or Carlo Erba (Milan,
Italy).Test products
Recombinant Met-G-CSF (BK0023) was produced using a
Bioker’s manufacturing technology at Eurogenetec S.A.,
Belgium, in GMP conditions by high biomass E.coli fer-
mentation according to a previously described protein fu-
sion technology starting from a gene coding for filgrastim
bearing an N-terminal enhancer peptidic tag [8]. Briefly,
LacZ8-PNP20-Kex-1-Met-G-CSF hybrid fusion protein
(where LacZ8 represents the first 8 aminoacids of the LacZ
protein fragment [UniProt/SwissProt accession Q37953],
PNP20 is a sequence coding for the first twenty amino acids
of E.coli purine nucleoside phosphorylase [9] and the N-
terminal methionine residue of filgrastim is immediately
preceded by a sequence coding for the short flexible pep-
tide -Glu-Ser-Ser-Met-Ser-Gly-Leu-Phe-Lys-Arg- ending
with a Lys-Arg basic dipeptide which in vitro is specifically
cleaved at C-terminal site of arginine by the endoprotease
ss-Kex-1-C611 to leave the mature sequence of filgrastim)
was expressed in E.coli as cytoplasmic inclusion bodies.
After isolation of inclusion bodies, the fusion protein was
dissolved in 7 M guanidine, renaturated by dilution, dia-
lyzed and cleaved by treatment with the patented recom-
binant endoprotease ss-Kex1-C611 [10] and the released
filgrastim was purified to homogeneity by column chroma-
tography to obtain a clinical grade preparation coded
BK0023. Bulk BK0023 in pH 4.5 buffered solution, was
sterile filtrated, formulated in glass vials containing for each
milliliter 300 μg filgrastim, 50 mg sorbitol, 0.04 mg
polysorbate 80, 0.59 g acetate ions 0.83 mg sodium ions
and stored at 2-8°C. The reference filgrastim was
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from a pharmacy.
Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) and Western Blotting
SDS-PAGE was carried out in reducing and non-reducing
conditions on polyacrylamide gels (4% stacking gel, 12%
running gel) prepared according to Laemmli [11]. Samples
were diluted 1:1 v/v with 62.5 mM Tris–HCl-pH 6.8-
25% glycerol-2% SDS-0.01% Bromophenol Blue ± 5% 2-
mercaptoethanol buffer and heated for 5 min at 95°C. Ten
microliters samples (3–5 μg of protein) were loaded in the
gels which, after the electrophoretic migration, were stained
with Coomassie Brilliant Blue R 250 and washed with
10% v/v acetic acid-15% v/v ethanol solution.
Western Blotting was carried out, after SDS-PAGE separ-
ation and electrophoretic transfer, using anti-G-CSF rabbit
polyclonal antibody (PeproTech, Hamburg, Germany) as
primary antibody and anti-rabbit goat antibody HRP conju-
gate (Santa Cruz Biotechnology, Heidelberg, Germany) as
secondary antibody.
Reversed Phase-High Pressure Liquid Chromatography
(RP-HPLC)
BK0023 purity and contamination with its oxidized forms
were detected by RP-HPLC of 3–5 μg/10 μl samples per-
formed on a Symmetry C18 300 Å column, 2.1 × 150
mm, 3.5 μm (Waters Corp., Milford Massachusetts, USA)
with a HP 1100 liquid chromatography system (Agilent
Technologies, Waldbronn, Germany) equipped with auto-
matic sample injection and UV detection at 215 nm. The
column was equilibrated in 46.3% buffer A (HPLC grade
H2O containing 0.1% trifluoroacetic acid) and 53.7% buf-
fer B (acetonitrile containing 0.08% trifluoroacetic acid).
Gradient elution was carried out at a flow rate of
0.285 ml/min and 53°C as follows: from 53.7% to 58.3%
buffer B in 8 min; from 58.3% to 63,3.6% buffer B in
8 min; from 63.3% to 72.7% buffer B in 6 min.
Size-Exclusion High-Pressure Liquid Chromatography (SE-
HPLC)
BK0023 contamination with its aggregated forms was de-
tected by SE-HPLC of 5 μl samples performed on a TSKgel
Super SW2000, 4 μm, 4.6 × 30 cm column (Tosho
Bioscience, Stuttgart, Germany) with a HP 1100 liquid
chromatography system and UV detection at 214 nm. The
column was equilibrated and isocratically eluted with
63 mM phospate-pH 7- 3% isopropanol mobile phase at a
flow-rate of 250 μl/min and 25°C.
Amino acid sequence analysis and peptide mapping
Amino acid sequences of BK0023 and Neupogen® were
compared by NH2-terminal amino acid sequence analysis
of the first 15 residues by standard Edman degradationprocedure on an automated Procise 610A Protein Sequen-
cer (Applied Biosystems, Foster City CA, USA) and by pep-
tide mapping after proteolysis in non-reducing and
reducing conditions with endoprotease Glu-C from S aur-
eus followed by RP-HPLC separation of resulting peptides
and MS/MS identification. Mass spectrometry was per-
formed in positive ion mode on a MALDI-TOF Reflex III
instrument (Bruker, Bremen, Germany).Assay of process derived contaminants
Endotoxin contamination of formulated BK0023 was
assayed by Lymulus Amoebocyte Lysate (LAL) test using
Pyrochrome LAL kit (Cape Code Inc, Falmouth, MA,
USA), while residual E.coli proteins were detected by
immunoenzymatic method assay using an E.coli HCP
Elisa kit (Cygnus Technologies. Wrentham, MA, USA).
Both tests were performed according to the manufac-
turers’ instructions.
Quantization of host/vector DNA contamination has
been performed under Good Laboratory Practice condi-
tions by an external contractor (NewLab Bioquality AG,
Erkrath, Germany).Stability study
A three months stability study of formulated BK0023 was
performed maintaining aliquots of product solutions at 5 ±
3°C and 25 ± 2°C. At time intervals, samples were assayed
by RP- and SE-HPLC to detect the appearance of new
minor degradation peaks.In vitro cell proliferation
Cell proliferation effect of BK0023 in comparison to
Neupogen® was measured on a murine myeloblastic NFS-
60 cell line according to a described colorimetric method
[12]. Briefly, NFS-60 cells were cultured at a confluence of
5 × 105 cells/ml in RPMI 1640 medium containing
200 mM L-glutamine, 1 mM Na-pyruvate, 10% FBS and
33 IU/ml of mouse IL 3 at 37°C, under a 5% CO2 humidi-
fied atmosphere. After a starvation period of 17 hours with-
out serum, 1 × 104 cells/well were seeded in triplicate in
microtiter plates and incubated for 48 hours with samples
in concentration ranging from 0.0015 to 5 ng/ml. At the
end of incubation, 20 μl of WST-1 cell proliferation reagent
were added and, after 4 hours of incubation, the formation
of soluble formazan dye was estimated by reading the ab-
sorbance at 450 nm with an ELISA plate reader. EC50 of
BK0023 and Neupogen were calculated from the sigmoidal
concentration-response curve using the GraphPad Prism
program (GraphPad Software, San Diego, CA, USA). Raw
data for the parallel line method were processed according
to the European Pharmacopoeia [13] and the results were
expressed as rate of BK0023 towards Neupogen®’s potency.
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The potencies of BK0023 and Neupogen® in displacing
125I-radiolabelled h-G-CSF (Amersham Biosciences,
Amersham, UK) bound to the G-CSF receptor were de-
termined using NFS-60 cell line as described [14]. The
experiments were carried out in duplicate by incubating
2.5 × 106 cells for 1 hour at 37°C in 150 μl of RPMI
1640 medium containing 10% FCS, 20 mM Hepes-
NaOH (pH 7.3), 500 pM [125I]G-CSF and increasing
concentrations of either BK0023 or Neupogen®.
After the incubation, the tubes were chilled on ice and
the mixtures were layered over 400 μl of phtalate oil
(dibutylphtalate: dioctylphtalate 3:2) in 1.5 ml Eppendorf
tubes and centrifuged at 6,000 g for 10 min at 4°C. Fol-
lowing aspiration of the aqueous and organic superna-
tants, the pellets were solubilized and mixed with
Formula-989 liquid scintillation cocktail (Perkin-Elmer,
Monza, Italy). The radioactivity was determined by
liquid scintillation counting in a TRI-CARB 1600TR li-
quid scintillation counter (Canberra-Packard, Cassina
de’ Pecchi, Italy) with an efficiency of 70%. Nonspecific
binding was determined in the presence of 500 nM un-
labeled r-G-CSF. Assays were performed in duplicate.
Immunoenzymatic analysis
BK0023 and Neupogen® concentrations were measured
in rat plasma samples by an ELISA method using the
commercial kit G-CSF Instant ELISA (Bender Med.
System, Vienna, Austria) according to the the manifac-
ture’s instructions.
Preclinical studies
Care and handling of animals used for preclinical studies
were in accordance with the provisions of the European
Economic Community Council Directive 86/209 recog-
nized and adopted by the Italian Government with the
Ministerial Decree No. 230/95-B and the NIH publica-
tion No. 85–23, revised in 1985.
Seven-nine week old Cr:CD Sprague Dawley rats and
13–18 week old New Zealand White female rabbits were
purchased from Charles River Srl (Calco, Italy) and sta-
bulated for acclimatization for about 4 and 2 weeks, re-
spectively, under thorough observation by a veterinarian.
Local tolerability of BK0023 in rabbits
Local tolerability after a single subcutaneous, intravenous
(into ear vein) or intramuscular injection of 300 μg/ml/
rabbit of formulated BK0023 was studied using 6 female
rabbits for each administration route.
The reaction to treatment was assessed by visual in-
spections on the day of treatment and on the day after
in the first 3 animals of each group and for 14 days in
the remaining animals. For microscopic evaluation, three
animals from each group were killed 48 hours aftertreatment, while the remaining animals from each group
were killed 14 days after dosing.
Repeated dose toxicity in rats
Rats of both sexes (10 males and 10 females for each group)
were treated for 4 weeks by daily subcutaneous injection of
formulated BK0023 or Neupogen® at dosage of 20, 100 and
500 μg/kg/day. Upon treatment completion, the animals
were observed for a further 4 week recovery period.
All the animals were submitted to routine clinical obser-
vations (local tolerance, clinical signs, body weight, food
and water consumption and ophthalmoscopic examin-
ation), standard laboratory analyses (blood chemistry,
haematology and urinalysis) and post-mortem examina-
tions (autopsy, organ weight and histology).
The pharmacodynamic parameters (white blood cells
and neutrophil counting) were determined by withdraw-
ing blood samples into tubes containing EDTA as anti-
coagulant before the start of treatment, at days 14 and
28 and upon completion of the recovery period. Blood
samples were stored at 4°C and used for counting white
blood cells (WBC) and neutrophils (ANC) on a Animal
Blood Counter ABC (ABX Diagnostic, Montpellier,
France) according to manufacturer’s instructions.
The toxicokinetic parameters were determined by
collecting serum samples at 1, 2, 4, 8 and 24 hours post-
dose on day 1 and on day 14 from all the treated
animals. The serum h-G-CSF concentration was mea-
sured using an ELISA technique. The formation of anti-
G-CSF antibodies was also evaluated by competitive
ELISA assay to examine whether a relationship existed
between antibody response and toxicokinetics.
Pharmacodynamics and pharmacokinetics in neutropenic
and non-neutropenic rats
Male Crl:CD rats were allocated in 12 groups of 10 animals,
while one group of 6 animals was used as a control. 6
groups of 10 animals were treated by intraperitoneal ad-
ministration at day −1 with a single 50 mg/kg dose of cyclo-
phosphamide to induce a marked increase of neutropenia,
lasting for several days and of comparable severity to WHO
grade III neutropenia in humans [15]. All animals were
then treated for 4 consecutive days by subcutaneous injec-
tions of 10, 30 and 100 μg/kg of BK0023 and Neupogen®
while control group was administered the vehicle alone.
The pharmacodynamic parameters (WBC and ANC)
were determined on blood samples withdrawn from the
tail vein of the first 6 rats taken from each group at the
following time points: pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and
12 days after the first dose.
In addition, pharmacokinetics was investigated by col-
lecting serum samples at 6 time points (pre-dose, 1, 2, 4,
8 and 24 hours after dosing) on day 1 of administration
from the remaining 4 animals of each treatment group.
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Phase I clinical study
Evaluation of pharmacodynamic equivalence and pharma-
cokinetics bioequivalence of BK0023 to Neupogen® were
assessed by an external Clinical Research Organization in
healthy male volunteers after single and multiple-dose sub-
cutaneous administration according to an experimental
protocol authorized by Canton Ticino Ethical Committee
and by the Swiss Central Health Authority.
Healthy men were treated with formulated BK0023 or
Neupogen® by subcutaneous injections at the following
doses according to a cross-over design in 2 consecutive
study periods, separated by a wash-out period of at least
28 days.
Group 1 (16 subjects): 2.5 μg/kg/day for 7 consecutive
days;
Group 2 (16 subjects): 5 μg/kg/day for 7 consecutive
days;
Group 3 (16 subjects): 10 μg/kg/day for 5 consecutive
days.
The primary clinical phase I study endpoints were as
follows:
1) Equivalence in terms of pharmacodynamic effects of
BK0023 versus Neupogen® assessed on baseline
adjusted increase of ANC.
2) Bioequivalence of pharmacokinetic profile of
BK0023 and Neupogen® assessed as peak
concentration of G-CSF (Cmax) and area under the
curve (AUC0-24 hours) for BK0023 and Neupogen at
both day 1 and at steady-state (last treatment day).
The secondary clinical phase I study endpoints were as
follows:
1) Equivalence in terms of induction of CD34+ cells
of BK0023 versus Neupogen® assessed on CD34+
peak concentration and AUCCD34+ versus time
from day 1 to 10 (2.5 and 5 μg/kg/day dose
groups) or from day 1 to 8 (10 μg/kg/day dose
group)
2) Bioequivalence in terms of G-CSF peak concentra-
tion of BK0023 and Neupogen® at both day 1 and at
steady-state (last treatment day)
3) Bioequivalence of pharmacokinetic parameters of
BK0023 and Neupogen® at both day 1 and at steady-
state (last treatment day) assessed as Tmax (time to
peak concentration), t1/2 (half life) and clearance.
4) Safety and tolerability of BK0023 as compared to
Neupogen®The study was designed as a group sequential clinical
trial in order to recalculate the correct sample size ne-
cessary to obtain statistically acceptable pharmacody-
namic and pharmacokinetic results for each group,
based on the intra subject variability, to achieve the pri-
mary study objectives.
Consequently, the study was conducted in two parts:
Part 1: 16 subjects per dose group were enrolled and
treated with both drug products in cross-over. The
pharmacodynamic and pharmacokinetic primary pa-
rameters, that is the AUC of ANC, the maximal
attained ANC and the serum filgrastim AUC on day 1
and at steady state were calculated after the end of the
second period of each dose group. A pharmacokineti-
cist, independent from the clinical study management
and from the sponsor, temporarily broke the blind with
the aim of evaluating intra-subject variability. The bio-
statistician re-calculated the sample size with the actual
study ad interim results in order to verify whether add-
itional subjects were needed to obtain statistically valid
results.
Part 2: On the basis of sample size re-calculation, an
additional number of subjects for each dose group was
enrolled: 16 subjects in the Group 1 (2.5 μg/kg/day), 20
subjects in the Group 2 (5 μg/kg/day) and 6 subjects in
the Group 3 (10 μg/kg/day).
The pharmacodynamic effects of both BK0023 and
Neupogen® were determined by ANC performed on whole
blood samples with a fully automated laser ADVIA 120
Haematology System (Bayer) which incorporates flow
cytometric principles and cytochemistry and by evaluating
the count of peripheral blood CD34 positive (CD34+)
hematopoietic stem cells by flow cytometric analysis as de-
scribed [16]. In fact, beside regulating granulopoiesis, G-
CSF is also able to mobilize CD34+ cells from the marrow
to the blood enabling the use of stem cell enriched periph-
eral blood in hematopoietic transplantation in lieu of bone
marrow cells [17].
The pharmacokinetic profile of filgrastim was deter-
mined in serum samples withdrawn after the 1st and the
last dose and stored frozen until the determination of G-
CSF concentration with a commercial ELISA kit
Statistical analysis of clinical and preclinical data
Results were analyzed using SAS® version 9.1.2 for Win-
dows software. The AUC of ANC and CD34+ cells and
their maximal attained counts were compared based on
analysis of variance for a cross-over design: the 95% CI
for the ratio of the averages (population geometric
means, if parameters are log-transformed) of the values
for the test and reference and the two onesided t-tests of
Schuirmann at the level of significance of 2.5%. Criteria
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CI of the ratio between treatment means fell within
85%-115% (or 85%-118% when parameters are log-
transformed). AUC and peak concentration of serum fil-
grastim were compared based on Latin-square analysis
of variance for a cross-over design: the 90% CI for the
ratio of the averages (population geometric means) of
the values for the test and reference and the two one-
sided t-tests of Schuirmann at the level of significance of
5%. Criteria for bioequivalence were that the 90% CI of
the treatment means ratio fell within the range of 80
to 125%. Pharmacokinetic data were calculated using
Kinetica™ Version 4.4.1 software (Thermo Electron Cor-
poration, USA); the area under the blood concentration-
time curve (AUC) was calculated using the trapezoidal
rule.
Experimental data of in vitro inhibition of radioactive
G-CSF binding by BK0023 and Neupogen to cell ex-
pressing G-CSF receptor were analyzed by using the
GraphPad Prism Program (San Diego, USA).
Information was given in both oral and written form
to each volunteer. Before being admitted to the clinical
study subjects expressed their consent to participate
singing copy of the written informed consent form.
Results
Analysis of physico-chemical properties
Purified BK0023 was characterized by a panel of
chemico-physical methods, including amino acid se-
quence analysis of NH2-terminal residues, RP-HPLC/
MS mapping of proteolytic products, MALDI-TOF-MS,
SDS-PAGE and Western blotting. The results showed
the absolute comparability to the clinically used filgras-
tim commercialized under the brand name of Neupo-
gen® as well as levels of process- and product-related
contaminations within the limits accepted by regulatory
authorities (Tables 1, 2 and 3).
The result of the stability study of formulated BK0023
are reported in Table 4. While the drug product ap-
peared stable at +5°C over a three month period, protein




First 15 N-terminal residues by automatic
degradation






RP-HPLCwhen the product was stored at 25°C. Consequently, all
BK0023 preparations were stored refrigerated as also
recommended for Neupogen®.
In vitro studies
Two studies, namely a cell proliferation assay and a radi-
oligand binding assay using the murine myeloblastic
NFS-60 cell-line were carried out to compare the
in vitro biological activity of BK0023 and Neupogen®.
The results of proliferation assay indicated that
BK0023 and Neupogen displayed in vitro the same bio-
logical potency as demonstrated by very close EC50
values (respectively 43.90 ng/ml ± 1.16 S.E.M. and
38.59 ng/ml ± 1.24 S.E.M.) overlapping at 95% confi-
dence intervals (with respective range of 31.97-60.29 and
24.61-60.41 ng/ml).
The radioreceptor assay also showed the same compe-
tition for BK0023 and Neupogen® towards radiolabelled
r-h-G-CSF bound to G-CSF receptors in NFS-60 cells
with estimated IC50 respectively of 4.52 ± 0.65 and 5.89 ±
0.49 ng/ml with no statistically significant difference
(Figure 1).
Local tolerability studies
Local tolerability was assessed in rabbits by a single
intravenous, subcutaneous and intramuscular adminis-
tration of 300 μg of BK0023, which is the highest con-
centration given in humans as a bolus injection. Slight
erythemas or oedemas, which were rapidly and com-
pletely reversible, were seen at sites of intravenous and
subcutaneous injections while no significant reaction
was observed in animals treated by intramuscular route.
In any case, no abnormality was detectable by micros-
copy examination as well as no clinical abnormal signs
were seen in any animal. These results indicate that
BK0023 is well tolerated locally.
Toxicity studies in rats
A repeated-dose toxicity study was performed in rats
to compare the toxicological profile of BK0023 and
Neupogen® administered subcutaneously for 4 weeks atn®
Results and notes
Edman Results agree with the expected sequence
lysis and Primary structure and disulfide bridge positions according to
the expected sequence
According to the calculated value
Migration profile comparable to Neupogen®
Elution profile comparable to Neupogen®
Binding to specific antibody as Neupogen®
Elution profile comparable to Neupogen®
Table 2 Product related impurities of purified bulk
BK0023 preparations
Impurity Method Result
BK0023 oxydized forms RP-HPLC < 1%
BK0023 aggregate forms SE-HPLC < 1%
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2–4, 10–20 and 50–100 times the clinical dose in humans
(5–10 μg/kg/day), respectively. In the same study we
compared the pharmacodynamic and the immunotoxi-
cologic profiles of the two products after 28 days of
daily subcutaneous administration. The study also in-
cluded a comparison of the toxicokinetic profiles after
14 days of treatment and an assessment following a
4-week recovery period.
The results showed that administration of BK0023 and
Neupogen® produced a comparable significant dose-
related increase in neutrophils and white blood cells
with respect to the control group (data not shown) indi-
cating that the animals received systemic exposure to
both products in a dose-related manner.
As regards the blood chemistry analyses, serum alka-
line phosphatase concentration significantly increased in
all the treated animals according to a dose-related trend
(Table 5). This effect may be correlated to osteoblast
and osteoclast cell function which, in turn, is indicative
of BK0023 and Neupogen® activity [18] .
Statistically significant increases in urea and creatinine
levels in females and decreases in chloride levels in
males were also observed in animals receiving the high-
est dose of Neupogen®, while other statistically signifi-
cant changes were sporadically recorded in animals
receiving the lower doses of BK0023 and Neupogen®.
However, these differences were considered too small to
be toxicologically meaningful and were therefore consid-
ered to have no toxicological implication.
No difference in body weight or food consumption
and no ophthalmic lesions were observed during the
study. The only anomalous in vivo observation was a
swelling of the lower hind limbs in both BK0023 and
Neupogen treated rats, which is an already described G-
CSF treatment related effect possibly due to induction of
fluid retention [19]. Of note, all changes observed during
treatment were no longer detected following the 4-weekTable 3 Process related impurities of formulated BK0023
preparations
Impurity Method Result
Bacterial endotoxins LAL test < 5 EU/mg
Host proteins (ECP) Immunoenzymatic assay < 20 ppm
Host/vector DNA Hybridation to degenerated probe < 100 pg/mg
EU Endotoxin unit, ppm part per million parts, pg picograms.recovery period, thereby confirming complete reversibil-
ity. The immunogenic response to BK0023 was
comparable to that of Neupogen® for anti-G-CSF immu-
noglobulins were detected in 3 serum samples out of
120 (1 male and 1 female rat treated with 20 and
500 μg/kg/day of BK0023 and 1 female rat treated with
500 μg/kg/day of Neupogen®) at the end of recovery
period. Moreover, in a separate study in rats, no specific
antibodies against r-h-G-CSF were detected following
daily administration of BK0023 at a concentration of
200 μg/kg/day over a 4-week period. The toxicokinetics
of BK0023 and Neupogen® assessed by comparing the
pharmacodynamic parameters after 1, 14 and 28 days of
treatment as well as at the end of 4-week recovery
period did not show any significant difference (data not
shown).
Pharmacodynamic and pharmacokinetic studies in normal
and neutropenic rats
Since G-CSF stimulates the production of bone marrow
cells interacting with a specific surface receptor, the in-
crease of ANC is a direct biochemical index of efficacy.
Thus, white blood cell count and ANC were determined
during 4 consecutive days of subcutaneous administra-
tions to normal and cyclophosphamide treated neutro-
penic rats at the doses of 10, 30 and 100 μg/kg of
BK0023 and Neupogen®. The dose range was selected to
induce a marked dose–response effect in terms of degree
and duration of neutrophil production stimulation in
order to detect any difference between BK0023 and
Neupogen®.
Pharmacodynamic evaluations demonstrated that
both BK0023 and Neupogen® boosted the proliferation
of white blood cells (WBC) and in particular of neu-
trophil cells, which appeared hypersegmented, indicat-
ing complete activation.
While both products yielded a comparable and dose–
related increase in total WBC and ANC, no difference
was observed regarding the other blood cells (lympho-
cytes, eosinophils, basophils, monocytes and large un-
stained cells) in either the neutropenic or normal rats
(data not shown). In normal rats, neutrophil levels in-
creased during the first day of treatment and returned to
normal values approximately 2 days after the last treat-
ment (Figure 2). Differently from normal rats, neutro-
penic rats exhibited a consecutive cycle of increasing
and decreasing of the neutrophil level in response to ei-
ther BK0023 or Neupogen® (Figure 3). The first increase
may be due to the mobilisation of the residual pool of
neutrophils after cyclophosphamide administration,
while the subsequent decrease may be related to the
cyclophosphamide-dependent reduction of neutrophil
production by the bone marrow blasts. The second in-
crease could depend on the effect of BK0023 and
Table 4 Stability of formulated BK0023 maintained at 5 and 25°C. Aliquots of samples were assayed at time 0, 1 and
2 months by RP-HPLC and SE-HPLC
Assay Storage time Temperature 5°C Temperature 25°C
BK0023 mg/ml Main peak% Sum of impurities% BK0023 mg/ml Main peak% Sum of impurities%
RP-HPLC 0 0.29 99.6 0.4 0.29 99.6 0.4
1 month 0.29 99.6 0.4 0.28 99.6 0.3
3 months 0.28 99.6 0.4 0.28 99.1 0.9
SE-HPLC 0 0.28 99.6 0.4 0.29 99.6 0.4
1 month 0.27 99.6 0.4 0.28 99.6 0.3
3 months 0.28 99.6 0.4 0.28 99.1 0.9
Aliquots of samples were assayed at time 0, 1 and 2 months by RP-HPLC and SE-HPLC. Peak purity and total impurities (or aggregates in the case of SE-HPLC
analysis) are reported as percentage of total peak areas.
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loid series.
The results of the pharmacokinetics study on day 1, sum-
marized in Table 6, showed that filgrastim was systemically
absorbed in both non-neutropenic and neutropenic rats
after both BK0023 and Neupogen® and that the animals
were similarly exposed to drugs; some sporadic differences
between treatments, shown in Table 6, can be ascribable to
the intrinsic animal variability or to different drug absorp-
tion after subcutaneous administration.
Summarizing, preclinical in vivo studies showed that
BK0023 and Neupogen® increased the proliferation of neu-
trophil cells in normal rats in a similar dose-dependent
manner while in neutropenic rats, both products were cap-
able of controlling myelotoxicity with the same dose-
dependent recovery of WBC and neutrophil counts. In
addition, pharmacokinetic parameters indicated that filgas-
tim was well absorbed in non-neutropenic and neutropenicFigure 1 Concentration-dependent inhibition of [125I]-G-CSF
binding by BK0023 (black circle) and Neupogen® (open circle)
in NFS-60 cells expressing G-CSF receptor. Data are reported as
percent of specific binding at each concentration of displacer and
are the means ± S.E.M. of four separate experiments. Statistical
analysis by Student’s t-test did not show any significant difference
between BK0023 and Neupogen®.rats and cleared from blood according to a comparable
pharmacokinetic profile after both BK0023 and Neupogen®.
Phase I clinical study
A phase I clinical study was performed in healthy male
volunteers treated with BK0023 and Neupogen® by sub-
cutaneous injection of 2.5 and 5 μg/kg/day for 7 con-
secutive days and of 10 μg/kg/day for 5 consecutive days
in order to assess the equivalence between the two prod-
ucts in terms of pharmacodynamic effect and the bio-
equivalence in terms of pharmacokinetic profile. The
count of neutrophils and CD34+ cells were quite similar
in both the rate and extent after a single injection of the
two products on day 1 and after a multiple injection
treatment of 5 days as shown, for example, in Figure 4
which refers to ANC. Concerning the CD34+ cell con-
centration, the baseline corrected values measured in 22
subjects up to day 8 after a 5-day treatment with daily
injection of 10 μg/kg of BK0023 or Neupogen were re-
spectively of 93,37 ± 35,33 and 95,40 ± 42,59 (mean
CD34+max/μL ± SD) and of 8166 ± 2917 and 8670 ± 3797
(mean AUCCD34+/μL x h ± SD). Data analysis performed
for each dose group showed no statistically difference
for ANC and CD34+ cell count as well as for areas under
the curve of both cell types (data not shown). In other
words, BK0023 was equivalent to Neupogen® in terms of
both AUC and maximal attained level of ANC and
CD34+ cells.
Time-dependent serum concentration profile of filgras-
tim measured by immunoenzymatic assay at day 1 and at
last day of subcutaneous treatment with BK0023 and Neu-
pogen at dose levels of 2.5, 5 and 10 μg/kg/day are reported
in Figure 5 which shows that pharmacokinetic profiles of
serum filgrastim were superimposable both at day 1 (after a
single administration) and at steady-state conditions (after
7 daily injections of 2.5 and 5.0 μg/kg/day or 5 daily injec-
tions of 10.0 μg/kg/day).
The corresponding calculated pharmacokinetic param-
eters Cmax and AUC0-24 hours for BK0023 and Neupogen
at both day 1 and at steady-state (last treatment day)
Table 5 Alkaline phosphatase (U/liter) assayed in blood of both female and male rats treated subcutaneously for
28 days with 20, 100 or 500 μg/kg/day with BK0023 or Neupogen®
Dose Control BK0023 Neupogen®
Males Females Males Females Males Females
0 μg/kg/day 440 ± 110 264 ± 69
20 μg/kg/day - - 669* ± 130 429 ± 135 773** ± 90 400** ± 50
100 μg/kg/day - - 1365** ± 303 747** ± 212 1022** ± 127 855** ± 166
500 μg/kg/day - - 2109.** ± 538 1227** ± 268 2378.** ± 647 1005** ± 367
Data are reported as mean values ± SD.
* = mean value of group is significantly different from the control group at P < 0.05.
** = mean value of group is significantly different from the control group at P < 0.01.
Statistical analysis was performed according to Dunnett’s test.
Crobu et al. BMC Pharmacology and Toxicology 2014, 15:7 Page 9 of 13
http://www.biomedcentral.com/2050-6511/15/7showed that parameters of BK0023 treated subjects were
similar to those of the Neupogen treated ones (Table 7).
For both products, a significant reduction of serum
levels of G-CSF (Cmax) and AUC was observed at the
last day of treatment versus that obtained at day 1. This
effect, which was already described for filgrastim, is due
to the enhanced G-CSF clearance through receptor
binding, internalization and degradation by the increased
neutrophil population [20].
Statistical evaluation of the pharmacokinetic bioequiv-
alence was also demonstrated by verifying that the 90%
confidence interval for the ratio of the means of AUC-
day1, AUCSS (steady-state AUC), Cmaxday1 and
CmaxSS (steady-state Cmax) between treatments met
the acceptance interval 80-125% and that the two one-
sided t-tests of Schuirmann did not detect any difference
at the level of significance of 5% [21].
Pharmacokinetics of filgrastim following treatment
with BK0023 and Neupogen® was proved not to differ
significantly also when other parameters (like elimin-
ation half-life t½, time of peak concentration Tmax and
systemic clearance Cl/body weight) were compared at
day 1 of treatment and at last day of subcutaneous treat-
ment by the non-parametric Kruskal-Wallis test [22].
In the whole clinical study, adverse effects were re-
ported for 70/102 subjects after treatment with BK0023,
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Figure 2 Mean neutrophile counts (× 109/l) obtained in groups of 10
30 and 100 μg/kg/day of BK0023 and Neupogen® are respectively sh
and triangles are respectively referred to control rat, BK0023 and Neu
Neupogen treated groups analysed by Student’s test. Significant difference
found at P < 0.05 (*) or P < 0.01 (**).Neupogen® for a total of 235 and 261 treatment-related
adverse effects for BK0023 and Neupogen treated sub-
jects, respectively.
The most frequent adverse effect was back pain of
mild to moderate intensity which reached a frequency of
65% of subjects with BK0023 at the dose of 5 μg/kg/day.
followed by bone pain which reached a frequency of 47%
of subjects after treatment with Neupogen® at the dose
of 10 μg/kg/day. Headache frequency between 8 and
16% of patients treated with at 2.5 to 10 μg/kg/day of
BK0023 and Neupogen was also observed. When com-
pared by χ2 test, no significant statistical difference was
detected in either the number of subjects experimenting
any adverse affect and the total number of treatment-
related adverse effects reported during the study. All ob-
served treatment-related adverse effects were expected
since they are linked to the mechanism of action of G-
CSF and were already described for filgrastim [23,24]. It
is worth noting that all observed adverse effects were
transient, resolved spontaneously and did not lead to
discontinuation or treatment withdrawal.
Discussion and conclusion
We report the preclinical and phase I clinical compari-
son of an intended biosimilar filgrastim or r-Met-G-CSF
(coded BK0023), produced according to an original re-
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Figure 3 Mean neutrophile counts (× 109/l) ± SD obtained in groups of 10 neutropenic rats treated for 4 days by subcutaneous
injections of 10, 30 and 100 μg/kg/day of BK0023 and Neupogen® are respectively shown in left, central and right panels where full
circles, squares and triangles are respectively referred to control rats, BK0023 and Neupogen. No significant difference was found
between BK0023 and Neupogen treated groups analysed by Student’s test. Significant differences between treated and control groups analysed
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http://www.biomedcentral.com/2050-6511/15/7Neupogen®, which is largely used for decreasing the dur-
ation of febrile neutropenia in oncological patients
treated with myelosuppressive anticancer drugs. Due to
the same analytical and structural profile, BK0023 is ex-
pected to display the same tolerability and toxicity pro-
file of Neupogen® as well as the same efficacy as
Neupogen® in controlling myelotoxicity induced by
chemotherapy during treatment of solid and haemato-
logical tumors
The results reported in this paper confirm that
BK0023 and Neupogen® display similar in vitro biological
potency in terms of both stimulation of proliferation of
the G-CSF dependent NFS-60 cell line and competi-
tion with radiolabeled r-h-G-CSF for binding to
G-CSF receptor in NFS-60 cells. BK0023, when locallyTable 6 Major pharmacokinetic parameters for BK0023
and Neupogen® administered to normal and
cyclophosphamide neutropenic rats following a single












BK0023 10 51 2 179 1.5
30 64 2 377 2.6
100 377 2 1582 2.6
Neupogen® 10 14 1 65 1.8
30 68 2 369 2.4
100 272 1 1121 2.2
Neutropenic rats
BK0023 10 27 2 134 1.9
30 84 2 410 1.7
100 444 2 1558 1.8
Neupogen® 10 31 2 132 2.0
30 87 2 485 2.5
100 309 2 1620 2.4
Abbreviations: AUC Area under the serum concentration-time curve from time
zero to infinity, Cmax Maximum observed serum concentration, Tmax time to
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Figure 4 Mean neutrophil counts (× 103/μl) ± SD measured in
human healthy volonteers treated for 7 days by subcutaneous
injections of BK0023 (triangles) and Neupogen® (circles) at
dosage of 2.5 μg/kg/day (upper panel) and 5.0 μg/kg/day
(central panel) and for 5 days by subcutaneous injections of
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Figure 5 Plasma level profiles of G-CSF (pg/ml) measured by immunoenzymatic assay at day 1 (solid lines) and at the last day of
treatment (dashed lines) for BK0023 2.5 μg/kg/day (A); Neupogen 2.5 μg/kg/day (B); BK0023 5 μg/kg/day (C); Neupogen 5 μg/kg/day
(D); BK0023 10 μg/kg/day (E); Neupogen 10 μg/kg/day (F).
Table 7 Pharmacokinetic parameters (mean ± SD) calculated at day 1 and after the last day of treatment (steady-state)
for human healthy volonteers treated for 7 days with subcutaneous injections of 2.5 and 5.0 μg/kg/day of BK0023 and
Neupogen® and for 5 days with subcutaneous injections of 10.0 μg/kg/day of BK0023 and Neupogen®
Product and dosages First treatment Steady-state
Cmax ng/ml AUC0-24 hoursng/ml · hour Cmax ng/ml AUC0-24 hoursng/ml · hour
BK0023 2.5 μg/kg/day 14.1 ± 1.4 113.6 ± 30.8 4.7 ± 1.6 32.8 ± 8.5
Neupogen 2.5 μg/kg/day 13.4 ± 3.9 111.9 ± 30.3 5.1 ± 2.0 33.7 · 9.6
BK0023 5 μg/kg/day 30.1 ± 9.1 276.7 ± 71.6 7.9 ± 4.4 51.2 ± 23.7
Neupogen 5 μg/kg/day 32.2 ± 10.7 295.0 ± 86.8 9.0 ± 5.2 55.3 ± 27.0
BK0023 10 μg/kg/day 60.1 ± 16.7 670.0 ± 154.9 25.1 ± 10.3 189.4 ± 69.7
Neupogen 10 μg/kg/day 56.5 ± 11.8 671.5 ± 122.5 25.1 ± 9.0 188.4 ± 52.2
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http://www.biomedcentral.com/2050-6511/15/7administered to rabbits at the maximal concentration
expected to be used clinically as a bolus injection, is well
tolerated without onset of systemic toxicity after single
intravenous, subcutaneous or intramuscular injection. In
this study, the subcutaneous and intravenous administra-
tion routes have been chosen since these are the most
common administration routes of filgrastim in humans
while the intramuscular route has been included in con-
sideration of accidental product exposure.
BK0023 and Neupogen® were also compared in a sub-
chronic toxicity study by subcutaneous administration in
rats, which are a relevant animal model for toxicological
studies since r-h-Met-G-CSF is pharmacologically active
in this species. In fact, data from literature show that r-
h-Met-G-CSF not only increases neutrophil counts in
peripheral blood but also enhances neutrophil functions
in rats [15].
The results of repeated dose toxicity in rats treated for
28 days with 20, 100 and 500 μg/kg/day (which corres-
pond respectively to 2–4, 10–20 and 50–100 times the
clinical dose of 5–10 μg/kg/day) showed for the two
products comparable toxicokinetic and immunotoxicolo-
gic profiles. Besides, no treatment-related effects were
observed at the post-treatment recovery period of
4 weeks so that the maximal administered dose of
500 μg/kg/day may be considered as No Observed
Adverse Effect Level (NOAEL) for both BK0023 and ref-
erence Neupogen®. Altogether, the results obtained in
this study indicate the pharma-toxicological comparabil-
ity of BK0023 and Neupogen®.
The in vivo studies on neutropenic and non-neutropenic
rats showed that both BK0023 and Neupogen® boosted the
proliferation of neutrophil cells in normal rats in a
dose-dependent manner while in neutropenic rats both
products are capable of controlling myelotoxicity with
dose-dependent recovery of neutrophils and white blood
cells. In preclinical studies, no significant difference be-
tween the two products was observed. Our data clearly
demonstrate that the biological activity in animal models of
BK0023 is comparable to that of Neupogen®.
Phase I clinical trial in healthy subjects was carried
out according to a multiple-dose, randomised, two-
period, cross-over design since there are 2 types of
pharmacokinetic non-linearity (non-proportional in-
crease with dose and time dependent non-linearity).
Dose levels of 2.5 and 5 μg/kg/day were chosen for
the pharmacodynamic study since data in the litera-
ture show a clear dose–response relationship in terms
of the pharmacodynamic parameters over this range
[23] while the dose of 10 μg/kg/day was chosen to
ensure that the investigated dose range was relevant
to the clinical indications and because it is usual in
the praxis for filgrastim. The subcutaneous adminis-
tration was chosen for the pharmacokinetic andpharmacodynamic bioequivalence study since this one
is the administration route most commonly used in
the clinical setting.
Pharmacodynamic, pharmacokinetic and safety of
BK0023 and Neupogen® were compared according to a
cross-over design in 2 consecutive periods with a wash-
out of at least 28 days between the last injection of
period I and the first of period II.
The results showed that BK0023 has the same phar-
macokinetic profile, efficacy and safety as the reference
commercial filgrastim Neupogen® and therefore could be
further developed to become a convenient option to
treat neutropenia in oncological patients.
Finally, the demonstration of bioequivalence between
BK0023 and commercial filgrastim enabled the prepar-
ation of a new long lasting site-specific monopegylated
filgrastim derivative as described elsewhere [25].
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